I don't understand. VXRT media release of 22JAN20 reported success of phase 2 influenza A challenge study in a randomized double-blind study using Vaxart oral tablet vaccine with FLUZONE (the current most efficacious flu vacine) as the comparator and a placebo control. That seems to be the gold standard for testing at this stage of development?
I know there is a long way to go before we have an approved vaccine (if ever), but it should have at least boosted the price of VXRT.
Or am I missing something fundamental - perhaps wishful thinking on my part makes me read things that are not there ( I am underwater in excess of $100K from the Biota fiasco, so I regularly indulgence myself in the what ifs).
- Forums
- ASX - By Stock
- BTA
- What did we get?
What did we get?, page-26
-
- There are more pages in this discussion • 52 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)